Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 4, 2009, Pages 1145-1153

  Figueroa Vega, Nicté ^a,b   Sanz Cameno, Paloma ^b   Moreno Otero, Ricardo ^b   Sánchez Madrid, Francisco ^c   Gonzalez Amaro, Roberto ^a   Marazuela, Mónica ^b,c  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTITHYROID AGENT; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 65249097347     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1571     Document Type: Article

References (41)

1. Weetman AP 2004 Autoimmune thyroid disease. Autoimmunity 37:337-340
2. Bidey SP, Hill DJ, Eggo MC 1999 Growth factors and goitrogenesis. J Endocrinol 160:321-332
3. Ramsden JD 2000 Angiogenesis in the thyroid gland. J Endocrinol 166:475-480
4. Szekanecz Z, Koch AE 2007 Mechanisms of disease: angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 3:635-643
5. Marazuela M, Sanchez-Madrid F, Acevedo A, Larranaga E, de Landazuri MO 1995 Expression of vascular adhesion molecules on human endothelia in autoimmune thyroid disorders. Clin Exp Immunol 102:328-334
6. Bartalena L, Wiersinga WM, Pinchera A 2004 Graves' ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 27:295-301
7. Garrity JA, Bahn RS 2006 Pathogenesis of Graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 142:147-153
8. Carmeliet P 2003 Angiogenesis in health and disease. Nat Med 9:653-660
9. Salcedo X, Medina J, Sanz-Cameno P, Garcia-Buey L, Martin-Vilchez S, Borque MJ, Lopez-Cabrera M, Moreno-Otero R 2005 The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 42:696-701
10. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, Bongarzone I 1999 Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155:1967-1976
11. Chen JX, Chen Y, DeBusk L, Lin W, Lin PC 2004 Dual functional roles of Tie-2/angiopoietin in TNF-α-mediated angiogenesis. Am J Physiol Heart Circ Physiol 287:H187-H195
12. Eklund L, Olsen BR 2006 Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 312:630 - 641
13. Fiedler U, Augustin HG 2006 Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27:552-558
14. Jones PF 2003 Not just angiogenesis-wider roles for the angiopoietins. J Pathol 201:515-527
15. Martin V, Liu D, Fueyo J, Gomez-Manzano C 2008 Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol 23:773-780
16. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG 2005 The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 118:771-780
17. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD 1997 Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60
18. Lobov IB, Brooks PC, Lang RA 2002 Angiopoietin-2 displays VEGF-depen- dent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99:11205-11210
19. Koch AE, Distler O 2007 Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 9:S3
20. Uchida T, Nakashima M, Hirota Y, Miyazaki Y, Tsukazaki T, Shindo H 2000 Immunohistochemical localisation of protein tyrosine kinase receptors Tie-1 and Tie-2 in synovial tissue of rheumatoid arthritis: correlation with angiogenesis and synovial proliferation. Ann Rheum Dis 59:607-614
21. Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M 2001 Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 116:713-720
22. Creamer D, Sullivan D, Bicknell R, Barker J 2002 Angiogenesis in psoriasis. Angiogenesis 5:231-236
23. Iitaka M, Miura S, Yamanaka K, Kawasaki S, Kitahama S, Kawakami Y, Kakinuma S, Oosuga I, Wada S, Katayama S 1998 Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 83:3908 -3912
24. Ramsden JD, Cocks HC, Shams M, Nijjar S, Watkinson JC, Sheppard MC, AhmedA, Eggo MC 2001 Tie-2 is expressed on thyroid follicular cells, is increased in goiter, and is regulated by thyrotropin through cyclic adenosine 3′,5′-monophosphate. J Clin Endocrinol Metab 86:2709-2716
25. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R 1989 Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 73:639-644
26. Antonelli A, Fallahi P, Nesti C, Pupilli C, Marchetti P, Takasawa S, Oka- moto H, Ferrannini E 2001 Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clin Exp Immunol 126:426-431
27. Donckier JE, Michel L, Delos M, HavauxX, VanBenedenR 2006 Interrelated overexpression of endothelial and inducible nitric oxide synthases, endothe- lin-1 and angiogenic factors in human papillary thyroid carcinoma. Clin En- docrinol (Oxf) 64:703-710
28. Sanz-Cameno P, Martin-Vilchez S, Lara-Pezzi E, Borque MJ, Salmeron J, Mu- noz de Rueda P, Solis JA, Lopez-Cabrera M, Moreno-Otero R 2006 Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. Am J Pathol 169:1215-1222
29. Gravallese EM, Pettit AR, Lee R, Madore R, Manning C, Tsay A, Gaspar J, Goldring MB, Goldring SR, Oettgen P 2003 Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor a. Ann Rheum Dis 62:100-107
30. DeBusk LM, Chen Y, Nishishita T, Chen J, Thomas JW, Lin PC 2003 Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor α-in- duced angiogenesis in rheumatoid arthritis. Arthritis Rheum 48: 2461-2471
31. Scott BB, Zaratin PF, Colombo A, Hansbury MJ, Winkler JD, Jackson JR 2002 Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol 29:230 -239
32. Markham T, Mullan R, Golden-Mason L, Rogers S, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ 2006 Resolution of endothelial activation and down- regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 54:1003-1012
33. Aplin AC, Gelati M, Fogel E, Carnevale E, Nicosia RF 2006 Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis. Physiol Genomics 27:20 -28
34. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, Sobke A, Herrmann M, Preissner KT, Vajkoczy P, Augustin HG 2006 Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat Med 12:235-239
35. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C, Naldini L 2007 Identification of proangiogenic TIE2-express- ing monocytes (TEMs) in human peripheral blood and cancer. Blood 109: 5276 -5285
36. Voskas D, Jones N, Van Slyke P, SturkC, Chang W, Haninec A, Babichev YO, Tran J, Master Z, Chen S, Ward N, Cruz M, Jones J, Kerbel RS, Jothy S, Dagnino L, Arbiser J, Klement G, Dumont DJ 2005 A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol 166:843-855
37. Sato K, Yamazaki K, Shizume K, Kanaji Y, Obara T, Ohsumi K, Demura H, Yamaguchi S, Shibuya M 1995 Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 96:1295-1302
38. Nagura S, Katoh R, Miyagi E, Shibuya M, Kawaoi A 2001 Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. Hum Pathol 32:10-17
39. Turner HE, Harris AL, Melmed S, Wass JA 2003 Angiogenesis in endocrine tumors. Endocr Rev 24:600-632
40. Ramsden JD, Buchanan MA, Egginton S, Watkinson JC, Mautner V, Eggo MC 2005 Complete inhibition of goiter in mice requires combined gene therapy modification of angiopoietin, vascular endothelial growth factor, and fibro- blast growth factor signaling. Endocrinology 146:2895-2902
41. Mitsutake N, Namba H, Takahara K, Ishigaki K, Ishigaki J, Ayabe H, Ya- mashita S 2002Tie-2andangiopoietin-1 expression in human thyroid tumors. Thyroid 12:95-99